{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:32:32Z","timestamp":1793431952224,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) in 2015 for treatment of non-small cell lung cancer (NSCLC). Our study was to explore the adverse events (AEs) caused by osimertinib through data mining of the US FDA Adverse Event Reporting System (FAERS), and provide reference for clinical safety. Data of osimertinib were collected from the FAERS database covering the period from first quarter of 2016 to the fourth quarter of 2021. Disproportionality analyses was employed to quantify the associated AE signals of osimertinib and detect the risk signals from the data in the FAERS database. Reporting odds ratio (ROR) was used to detect the risk signals from the data in the FAERS database. The definition relied on system organ class (SOCs) and preferred terms (PTs) by the Medical Dictionary for Regulatory Activities (MedDRA). Totally, 9,704,33 reports were collected from the FAERS database, 10,804 reports of osimertinib were identified as the \u2018primary suspected (PS)\u2019 AEs. Osimertinib induced AEs occurred in 27 organ systems. 68 significant disproportionality PTs satisfying with the four algorithms were retained at the same time. Unexpected significant AEs such as scrotal volvulus, hepatic function abnormal, venous thromboembolisms might also occur. The median onset time of osimertinib-associated AEs was 58\u00a0days (interquartile range [IQR] 14\u2013212\u00a0days), and the majority of the AEs occurred within the first 30\u00a0days after osimertinib initiation. Our study found significant new AEs signals of osimertinib and might provide support for clinical monitoring and risk identification of osimertinib.<\/jats:p>","DOI":"10.1038\/s41598-022-23834-1","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T06:07:00Z","timestamp":1668492420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib"],"prefix":"10.1038","volume":"12","author":[{"given":"Yanchao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"23834_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1634\/theoncologist.13-S1-28","volume":"13","author":"TE Stinchcombe","year":"2008","unstructured":"Stinchcombe, T. E. & SocinskI, M. A. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13, 28\u201336 (2008).","journal-title":"Oncologist"},{"key":"23834_CR2","first-page":"1710","volume":"11","author":"CF Mountain","year":"2010","unstructured":"Mountain, C. F. Revisions in the international system for staging lung. Cancer 11, 1710\u20131717 (2010).","journal-title":"Cancer"},{"key":"23834_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2018.11.029","volume":"127","author":"X Guo","year":"2019","unstructured":"Guo, X. et al. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer 127, 84\u201389 (2019).","journal-title":"Lung Cancer"},{"key":"23834_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/annonc\/mdz437.024","volume":"30","author":"SG Wu","year":"2019","unstructured":"Wu, S. G. et al. An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study-Science Direct. Ann. Oncol. 30, 168 (2019).","journal-title":"Ann. Oncol."},{"key":"23834_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/annonc\/mdz437.015","volume":"30","author":"MJ Hochmair","year":"2019","unstructured":"Hochmair, M. J. et al. Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study. Ann. Oncol. 30, 165 (2019).","journal-title":"Ann. Oncol."},{"key":"23834_CR6","unstructured":"Astrazeneca pharmaceuticals. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. Revised April 2018. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208065s008lbl.pdf."},{"key":"23834_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"key":"23834_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"key":"23834_CR9","doi-asserted-by":"crossref","unstructured":"Thein, K. Z., Swarup, S., Ball, S., Quirch, M., Vorakunthada, Y., Htwe, K. K., et al. 1388p incidence of cardiac toxicities in patients with advanced non-small cell lung cancer treated with osimertinib: A combined analysis of two phase III randomized controlled trials. Ann. Oncol. 29, suppl_8 (2018).","DOI":"10.1093\/annonc\/mdy292.011"},{"key":"23834_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107498","volume":"95","author":"C Chen","year":"2021","unstructured":"Chen, C. et al. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int. Immunopharmacol. 95, 107498 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"23834_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13331","volume":"73","author":"L Meng","year":"2019","unstructured":"Meng, L. et al. Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system. Int. J. Clin. Pract. 73, e13331 (2019).","journal-title":"Int. J. Clin. Pract."},{"key":"23834_CR12","doi-asserted-by":"crossref","unstructured":"Anand, K., Ensor, J., Trachtenberg, B., et al. Osimertinib induced cardio-toxicity: A retrospective review of FDA adverse events reporting system (FAERS). J. Clin. Oncol. 37(15_suppl), 9044 (2019).","DOI":"10.1200\/JCO.2019.37.15_suppl.9044"},{"key":"23834_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1159\/000430307","volume":"36","author":"S Yuliang","year":"2015","unstructured":"Yuliang, S. et al. DNA repair gene polymorphisms in relation to non-small cell lung cancer survival. Cell Physiol. Biochem. 36, 1419\u20131429 (2015).","journal-title":"Cell Physiol. Biochem."},{"key":"23834_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.steroids.2005.02.017","volume":"70","author":"RJ Pietras","year":"2005","unstructured":"Pietras, R. J. et al. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70, 372\u2013381 (2005).","journal-title":"Steroids"},{"key":"23834_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1440-1843.2005.00723.x","volume":"10","author":"W Lam","year":"2010","unstructured":"Lam, W. Lung cancer in Asian women-the environment and genes. Respirology 10, 408\u2013417 (2010).","journal-title":"Respirology"},{"key":"23834_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1349-7006.2004.tb02203.x","volume":"95","author":"J Yokota","year":"2010","unstructured":"Yokota, J. & Kohno, T. Molecular footprints of human lung cancer progression. Cancer Sci. 95, 197\u2013204 (2010).","journal-title":"Cancer Sci."},{"key":"23834_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"K Riihim","year":"2014","unstructured":"Riihim, K. et al. Metastatic sites and survival in lung cancer. Lung Cancer 86, 78 (2014).","journal-title":"Lung Cancer"},{"key":"23834_CR18","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1111\/1759-7714.13127","volume":"10","author":"M Fan","year":"2019","unstructured":"Fan, M., Mo, T., Shen, L. & Yang, L. Osimertinib-induced severe interstitial lung disease: A case report. Thoracic Cancer. 10, 1657\u20131660 (2019).","journal-title":"Thoracic Cancer."},{"key":"23834_CR19","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.2169\/internalmedicine.8467-16","volume":"56","author":"Y Matsumoto","year":"2017","unstructured":"Matsumoto, Y. et al. Interstitial lung disease induced by osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer. Intern. Med. 56, 2325\u20132328 (2017).","journal-title":"Intern. Med."},{"key":"23834_CR20","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/ijms22020792","volume":"22","author":"T Ohmori","year":"2021","unstructured":"Ohmori, T., Yamaoka, T., Ando, K., Kusumoto, S. & Sagara, H. Molecular and clinical features of egfr-tki-associated lung injury. Int. J. Mol. Sci. 22, 792 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"23834_CR21","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/j.jtho.2016.08.144","volume":"11","author":"SA Noonan","year":"2016","unstructured":"Noonan, S. A., Sachs, P. B. & Camidge, D. R. Transient asymptomatic pulmonary opacities occurring during osimertinib treatment. J. Thorac. Oncol. 11, 2253\u20132258 (2016).","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl 2","key":"23834_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/sj.bjc.6602063","volume":"91","author":"P Camus","year":"2004","unstructured":"Camus, P., Kudoh, S. & Ebina, M. Interstitial lung disease associated with drug therapy. Br. J. Cancer. 91(Suppl 2), 18\u201323 (2004).","journal-title":"Br. J. Cancer."},{"key":"23834_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10637-016-0389-9","volume":"35","author":"N Mamesaya","year":"2016","unstructured":"Mamesaya, N. et al. Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody. Investig. New Drugs 35, 105\u2013107 (2016).","journal-title":"Investig. New Drugs"},{"key":"23834_CR24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1089\/ars.2020.8055","volume":"34","author":"CC Dessalvi","year":"2020","unstructured":"Dessalvi, C. C. et al. Antioxidant approach as a cardioprotective Strategy in chemotherapy-Induced cardiotoxicity. Antioxid. Redox. Signal. 34, 572\u2013588 (2020).","journal-title":"Antioxid. Redox. Signal."},{"key":"23834_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jjco\/hyx071","volume":"47","author":"K Tajiri","year":"2017","unstructured":"Tajiri, K., Aonuma, K. & Sekine, I. Cardiovascular toxic effects of targeted cancer therapy. Jpn. J. Clin. Oncol. 47, 779\u2013785 (2017).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"23834_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijcard.2007.01.010","volume":"125","author":"K Knobloch","year":"2008","unstructured":"Knobloch, K. et al. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. Int. J. Cardiol. 125, 113\u2013115 (2008).","journal-title":"Int. J. Cardiol."},{"key":"23834_CR27","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1021\/acs.chemrestox.0c00005","volume":"33","author":"A Alhoshani","year":"2020","unstructured":"Alhoshani, A. et al. EGFR inhibitor gefitinib induces cardiotoxicity through the modulation of cardiac PTEN\/Akt\/FoxO3a pathway and reactive metabolites formation: In vivo and in vitro rat studies. Chem. Res. Toxicol. 33, 1719\u20131728 (2020).","journal-title":"Chem. Res. Toxicol."},{"key":"23834_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000073","volume":"1","author":"NF Pond\u00e9","year":"2016","unstructured":"Pond\u00e9, N. F., Lambertini, M. & Azambuja, E. D. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open. 1, e000073 (2016).","journal-title":"ESMO Open."},{"key":"23834_CR29","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.2169\/internalmedicine.8344-16","volume":"56","author":"H Watanabe","year":"2017","unstructured":"Watanabe, H. et al. Congestive heart failure during osimertinib treatment for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Intern. Med. 56, 2195\u20132197 (2017).","journal-title":"Intern. Med."},{"key":"23834_CR30","doi-asserted-by":"publisher","first-page":"117954681986644","DOI":"10.1177\/1179546819866445","volume":"13","author":"IE Perez","year":"2019","unstructured":"Perez, I. E. et al. Cancer therapy-related cardiac dysfunction: An overview for the clinician. Clin. Med. Insights Cardiol. 13, 117954681986644\u2013117954681986644 (2019).","journal-title":"Clin. Med. Insights Cardiol."},{"key":"23834_CR31","doi-asserted-by":"crossref","unstructured":"Kunimasa, K., Kimura, M., Oboshi, M., et al. MO2\u201316\u20132 Irreversible severe cardiotoxicities except for QTc interval prolongation associated with Osimertinib. Ann. Oncol. 30, vi109 (2019)","DOI":"10.1093\/annonc\/mdz338.081"},{"key":"23834_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jaccao.2020.01.003","volume":"2","author":"AJ Piper-Vallillo","year":"2020","unstructured":"Piper-Vallillo, A. J. et al. Heart failure associated with the epidermal growth factor receptor inhibitor osime rtinib. JACC Cardio Oncol. 2, 119\u2013122 (2020).","journal-title":"JACC Cardio Oncol."},{"key":"23834_CR33","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1042\/CS20200302","volume":"134","author":"C Sadasivan","year":"2020","unstructured":"Sadasivan, C. et al. Cardiovascular toxicity of PI3K\u03b1 inhibitors. Clin. Sci. (Lond.) 134, 2595\u20132622 (2020).","journal-title":"Clin. Sci. (Lond.)"},{"key":"23834_CR34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11523-020-00727-9","volume":"15","author":"AK Seghers","year":"2020","unstructured":"Seghers, A. K., Cuyle, P. J. & Cutsem, E. V. Molecular targeting of a BRAF mutation in pancreatic ductal adenocarcinoma: Case report and literature review. Target Oncol. 15, 407\u2013410 (2020).","journal-title":"Target Oncol."},{"key":"23834_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/CMR.0000000000000090","volume":"24","author":"E Pisareva","year":"2014","unstructured":"Pisareva, E. et al. Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma. Melanoma Res. 24, 322\u2013331 (2014).","journal-title":"Melanoma Res."},{"key":"23834_CR36","first-page":"6997","volume":"62","author":"MS Brose","year":"2002","unstructured":"Brose, M. S. et al. BRAFand KRAS mutations in human lung cancer and melanoma. Cancer Res. 62, 6997\u20137000 (2002).","journal-title":"Cancer Res."},{"key":"23834_CR37","first-page":"7001","volume":"62","author":"K Naoki","year":"2002","unstructured":"Naoki, K. et al. Missense mutations of BRAF gene in human lung adenocarcinoma. Cancer Res. 62, 7001\u20137003 (2002).","journal-title":"Cancer Res."},{"key":"23834_CR38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2217\/fon.13.16","volume":"9","author":"M Arcangelo","year":"2013","unstructured":"Arcangelo, M., Incecco, A. & Cappuzzo, F. Rare mutations in non-small-cell lung cancer. Future Oncol. 9, 699\u2013711 (2013).","journal-title":"Future Oncol."},{"key":"23834_CR39","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","volume":"17","author":"G Goss","year":"2016","unstructured":"Goss, G. et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 17, 1643\u20131652 (2016).","journal-title":"Lancet Oncol."},{"key":"23834_CR40","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1124\/mol.110.065839","volume":"78","author":"WC Teng","year":"2010","unstructured":"Teng, W. C. et al. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol. Pharmacol. 78, 693\u2013703 (2010).","journal-title":"Mol. Pharmacol."},{"key":"23834_CR41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","volume":"29","author":"CF Spraggs","year":"2011","unstructured":"Spraggs, C. F. et al. HLA-DQA1\/02:01 is amajor risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29, 667\u2013673 (2011).","journal-title":"J. Clin. Oncol."},{"key":"23834_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14309\/crj.0000000000000011","volume":"6","author":"I Gonz\u00e1lez","year":"2019","unstructured":"Gonz\u00e1lez, I. & Chatterjee, D. Histopathological features of drug-induced liver injury secondary to osimertinib. ACG Case Rep. J. 6, 1\u20133 (2019).","journal-title":"ACG Case Rep. J."},{"key":"23834_CR43","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s10637-018-0608-7","volume":"36","author":"R Hirabayashi","year":"2018","unstructured":"Hirabayashi, R., Fujimoto, D., Satsuma, Y., Hirabatake, M. & Tomii, K. Successful oral desensitization with osimertinib following osimertinib induced fever and hepatotoxicity: A case report. Investig. New Drugs 36, 952\u2013954 (2018).","journal-title":"Investig. New Drugs"},{"key":"23834_CR44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0032-1329535","volume":"25","author":"D Gingold","year":"2012","unstructured":"Gingold, D. & Murrell, Z. Management of colonic volvulus. Clin. Colon Rectal Surg. 25, 236\u2013244 (2012).","journal-title":"Clin. Colon Rectal Surg."},{"key":"23834_CR45","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3389\/fonc.2020.00510","volume":"10","author":"T Patil","year":"2020","unstructured":"Patil, T. et al. Cecal volvulus as a rare complication of osimertinib dosed at 160 mg in patients with EGFR-mutant non-small cell lung cancer. Front Oncol. 10, 510 (2020).","journal-title":"Front Oncol."},{"key":"23834_CR46","unstructured":"Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical Oncology clinical practice guideline update 2014. J. Clin. Oncol. 33, 654e6 (2015)."},{"key":"23834_CR47","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1002\/ijc.27979","volume":"132","author":"WX Qi","year":"2012","unstructured":"Qi, W. X. et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis. Int. J. Cancer 132, 2967\u20132974 (2012).","journal-title":"Int. J. Cancer"},{"key":"23834_CR48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.resinv.2020.11.007","volume":"59","author":"T Hotta","year":"2021","unstructured":"Hotta, T. et al. Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism. Respir. Investig. 59, 327\u2013334 (2021).","journal-title":"Respir. Investig."},{"key":"23834_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40801-021-00268-1","volume":"9","author":"C Teng","year":"2022","unstructured":"Teng, C. & Frei, C. R. Delirium associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Drugs Real World Outcomes 9, 23\u201329 (2022).","journal-title":"Drugs Real World Outcomes"},{"key":"23834_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu, Y. et al. Post-marketing safety concerns with secukinumab: A disproportionality analysis of the FDA Adverse Event Reporting System. Front Pharmacol. 13, 862508 (2022).","journal-title":"Front Pharmacol."},{"key":"23834_CR51","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","volume":"14","author":"Y Shu","year":"2022","unstructured":"Shu, Y., He, X., Liu, Y., Wu, P. & Zhang, Q. A real-world disproportionality analysis of olaparib: Data mining of the public version of FDA Adverse Event Reporting System. Clin. Epidemiol. 14, 789\u2013802 (2022).","journal-title":"Clin. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23834-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23834-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23834-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T21:15:45Z","timestamp":1668633345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23834-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["23834"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-23834-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"9 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19555"}}